Latest Immunic Therapeutics News & Updates

See the latest news and media coverage for Immunic. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Immunic Therapeutics (Immunic)

Clinical-stage biopharmaceutical company developing oral immunology therapies

imux.com
Headquarters
New York City, United States
Founded year
2016
Company type
Public company
Number of employees
110–200
Industry
Pharmaceuticals

Last updated

Latest news about Immunic Therapeutics (Immunic)

In short: Immunic reported a $42.3 million third-quarter loss and said ENSURE data were due in December 2026.

Company announcements

Immunic

Immunic reports 2025 net loss of $97.2 million

It raised $200 million upfront in an oversubscribed private placement of up to $400 million and expects phase 3 ENSURE top-line data by end-2026.

Unlock all announcements with a

Media coverage

StreetInsider

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

Immunic's second asset is IMU-935, an orally available small molecule inverse agonist of RORγt, a nuclear receptor known to influence the production of cytokines involved...

Unlock all articles with a

Never miss news about Immunic

Track Immunic and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.